http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yuzo Nakano (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Yoshiko Nakano,Toshitatsu Takao,Yoshinori Morita,Shinwa Tanaka,Takashi Toyonaga,Eiji Umegaki,Yuzo Kodama 대한소화기내시경학회 2020 Clinical Endoscopy Vol.53 No.5
Background/Aims: Mucosal cutting biopsy (MCB) is useful for the histopathological diagnosis of gastric subepithelial tumors (SETs). However, there is little information on cases in which MCB did not establish a diagnosis. In the current study, we aimed to investigatethe characteristics of cases in which MCB was unsuccessful. Methods: Cases in which MCB was used to histopathologically diagnose gastric SETs at Kobe University Hospital between August 2012and October 2018 were retrospectively reviewed. Results: Forty-five cases in which MCB was used to diagnose 43 gastric SETs in 43 patients were analyzed. The median tumor sizewas 20 mm (range, 8–50 mm). Pathological examinations resulted in definitive and suspected diagnoses and no diagnosis in 29(gastrointestinal stromal tumor: n=17, leiomyoma: n=7, aberrant pancreas: n=3, others: n=2), 6, and 10 cases, respectively. Failure toexpose the tumor according to retrospective examinations of endoscopic images was significantly associated with no diagnosis. Otherpossible explanations included a less elevated tumor, biopsy of the surrounding field instead of the tumor due to the mobility, and poorendoscope maneuverability due to the tumor being close to the cardia. Conclusions: Clear exposure of gastric SETs during MCB may improve the diagnostic rate of such examinations.
-
Arata Sakai,Hideyuki Shiomi,Takao Iemoto,Ryota Nakano,Takuya Ikegawa,Takashi Kobayashi,Atsuhiro Masuda,Yuzo Kodama 대한소화기내시경학회 2020 Clinical Endoscopy Vol.53 No.4
In this study, we assessed a series of our cases in which endoscopic self-expandable metal stents (SEMSs) were used to treat malignantafferent loop obstruction (ALO) that arose after pancreaticoduodenectomy (PD). We retrospectively examined the records of 7 patientswho underwent endoscopic SEMS placement for malignant ALO following PD. Clinical success was achieved in all cases. The medianprocedure time was 30 min (range, 15–50 min). There were no cases of stent occlusion, and no procedure-related adverse events wereencountered. All patients died of their primary disease, and the median overall survival period was 155 days (range, 96–374 days). Are-intervention involving endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting was performed forobstructive jaundice and acute cholangitis in 1 case. In conclusion, endoscopic SEMS placement may be an effective and safe treatmentfor malignant ALO that arises after PD.
-
Hideto Ueki,Takuto Hara,Yasuyoshi Okamura,Yukari Bando,Tomoaki Terakawa,Junya Furukawa,Kenichi Harada,Yuzo Nakano,Masato Fujisawa 대한비뇨의학회 2022 Investigative and Clinical Urology Vol.63 No.4
Purpose: Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab. Materials and Methods: This study evaluated 96 patients with RCC who received nivolumab. The SMI and PMI were calculated for each patient and normalized for stature by use of the following formulas: SMI (cm2/m2)=([skeletal muscle cross-sectional area at the level of L3]/[height]2) and PMI (cm2/m2) = ([left-right sum of the psoas muscle areas at the level of L3]/[height]2). The relationship of the clinical variables with progression-free survival and overall survival (OS) was examined using a Cox proportional hazards model. Results: According to the SMI-based definition of sarcopenia, 74.0% of patients had sarcopenia. However, according to the PMI-based definition of sarcopenia, only 34.3% of patients were diagnosed with sarcopenia. Multivariate analysis identified sarcopenia based on PMI (hazard ratio [HR], 3.85; 95% confidence interval [CI], 2.04–7.26; p<0.001) and International Metastatic RCC Database Consortium poor risk status (HR, 1.90; 95% CI, 1.03–3.50; p=0.041) as significant and independent prognostic factors of OS. Conclusions: PMI-based sarcopenia is a significant prognostic factor for OS in patients with RCC who receive nivolumab therapy.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
